Swati Bharadwaj, MD
Rheumatology · Phoenix, AZNPI 1194771931
Payments from drug & device makers
Across 994 payments — averaging $3402.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.3M
- Amgen$681K
- GSK$499K
- Novartis$455K
- UCB SA$238K
- Bristol Myers Squibb$60K
- plus $168K from 31 others
Across 3 payments — averaging $62.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$187
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 41 | $1,281,224 |
| Amgen(2 entities) | 223 | $680,841 |
| GSK | 234 | $499,005 |
| Novartis | 16 | $454,919 |
| UCB SA | 32 | $238,164 |
| Bristol Myers Squibb | 6 | $60,296 |
| Gilead | 29 | $35,359 |
| Janssen Research & Development, LLC | 9 | $33,344 |
| Sanofi US Services Inc. | 93 | $33,104 |
| Radius Health, Inc. | 43 | $29,991 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $20,557 |
| EMD Serono, Inc. | 5 | $6,585 |
| Mallinckrodt Enterprises LLC | 1 | $2,500 |
| Sun Pharmaceutical Industries Inc. | 2 | $2,400 |
| AbbVie | 141 | $1,964 |
| E.r. Squibb & Sons, L.L.C. | 22 | $368 |
| UCB, Inc. | 14 | $297 |
| Genentech USA, Inc. | 18 | $284 |
| Pfizer | 12 | $219 |
| Sanofi | 7 | $178 |
| Johnson & Johnson(3 entities) | 10 | $159 |
| AstraZeneca | 8 | $106 |
| Boehringer Ingelheim | 3 | $93 |
| Medtronic | 1 | $89 |
| Organon | 5 | $68 |
| Lilly USA, LLC | 3 | $59 |
| Pacira Therapeutics, Inc. | 2 | $32 |
| Mylan Institutional Inc. | 1 | $27 |
| Ferring Pharmaceuticals Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Aurinia Pharma U.S., Inc. | 1 | $25 |
| Sobi, Inc | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Abbott | 1 | $17 |
| Saluda Medical Americas, Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
How this compares
$3,382,428 in reported general payments places this provider in the 95th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Phoenix
- Nehad SolomanPhoenix$4.8M
- John TesserPhoenix$4.8M
- Nikila KumarPhoenix$3.1M
- Saima ChohanPhoenix$1.9M
- Matthew HerrmannPhoenix$408K
- Paul CaldronPhoenix$236K
- Ramina Jajoo-FrindrichPhoenix$87K
- Trent SmithPhoenix$9K
- Alan MallacePhoenix$4K
- Mona AminGlendale$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.